Myovant Sciences' Relugolix Combo Tablet For Uterine Fibroids Scores EMA Backing For Approval

by Vandana Singh, Benzinga Editor

May 21, 2021 3:52 PM | 1 min read

European Medicines Agency's advisory committee issued a positive opinion recommending the approval of Myovant Sciences Ltd's MYOV Ryeqo (relugolix, estradiol, and norethindrone acetate) for uterine fibroids.
The final decision on the application is expected to be available in approximately two months.
Gedeon Richter will commercialize Ryeqo for uterine fibroids, if approved, in Europe under an agreement announced in March 2020.
Relugolix combination tablet for uterine fibroids is also under review by the FDA with a target action date of June 1.
Price Action: MYOV shares are up 2.56% at $22.81 during the market session on the last check Friday.

Posted In: Biotech News Health Care FDA Movers Trading Ideas General Briefs European Medicines Agency (EMA)Uterine Fibroids

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.